| GluR2 endocytosis-dependent protein degradation in the amygdala mediates memory updating NC Ferrara, TJ Jarome, PK Cullen, SA Orsi, JL Kwapis, S Trask, ... Scientific Reports 9 (1), 5180, 2019 | 42 | 2019 |
| Distinct subcellular changes in proteasome activity and linkage-specific protein polyubiquitination in the amygdala during the consolidation and reconsolidation of a fear memory SA Orsi, RK Devulapalli, JL Nelsen, T McFadden, R Surineni, TJ Jarome Neurobiology of learning and memory 157, 1-11, 2019 | 33 | 2019 |
| Males and females differ in the regulation and engagement of, but not requirement for, protein degradation in the amygdala during fear memory formation R Devulapalli, N Jones, K Farrell, M Musaus, H Kugler, T McFadden, ... Neurobiology of learning and memory 180, 107404, 2021 | 28 | 2021 |
| Males and females differ in the subcellular and brain region dependent regulation of proteasome activity by CaMKII and protein kinase A RK Devulapalli, JL Nelsen, SA Orsi, T McFadden, S Navabpour, N Jones, ... Neuroscience 418, 1-14, 2019 | 15 | 2019 |
| TFE3-splicing factor fusions represent functional drivers and druggable targets in translocation renal cell carcinoma NP Damayanti, RA Cordova, C Rupert, I Delle Fontane, L Shen, S Orsi, ... Cancer Research 84 (8), 1286-1302, 2024 | 1 | 2024 |
| Dietary interventions selectively target dysregulated metabolism and reveal metabolic vulnerabilities in preclinical models of advanced renal cell carcinoma. S Orsi, M Chang, I Delle Fontane, A Jawadwala, S Colligan, F De Nigris, ... Journal of Clinical Oncology 42 (16_suppl), e16545-e16545, 2024 | | 2024 |
| Metabolic rewiring induced by protein or calorie restriction provides unique therapeutic vulnerabilities in translocation and select clear cell renal cell carcinomas SA Orsi, C Rupert, S Colligan, M Chang, A Jawadwala, ID Fontane, ... Cancer Research 84 (6_Supplement), 1786-1786, 2024 | | 2024 |
| The antihistamine terfenadine inhibits TFE3 dimerization, has antitumor activity and synergizes with tyrosine kinase inhibitors in translocation renal cell carcinoma ID Fontane, R Cordova, C Rupert, S Orsi, A Jawadwala, DE Heppener, ... Cancer Research 84 (6_Supplement), 7580-7580, 2024 | | 2024 |
| Therapeutic targeting of metabolic dysfunction by amino acid restriction and alternate day fasting in renal cell carcinoma models. S Orsi, C Rupert, M Chang, S Colligan, A Jawadwala, I Delle Fontane, ... Journal of Clinical Oncology 42 (4_suppl), 469-469, 2024 | | 2024 |
| Abstract A009: Therapeutic targeting of P2× 4 receptor and mitochondrial metabolism in clear cell renal carcinoma S Orsi, C Rupert, R Pili, F De Nigris Cancer Research 83 (16_Supplement), A009-A009, 2023 | | 2023 |
| A mechanistic study of the TFE3-splicing machinery gene fusions reveals a new druggable target for translocation renal cell carcinoma N Damayanti, S Orsi, R Cordova, C Rupert, L Shen, WM Linehan, ... Cancer Research 83 (7_Supplement), 4495-4495, 2023 | | 2023 |
